Sustainable Insight Capital Management LLC Makes New Investment in Johnson & Johnson (NYSE:JNJ)

Sustainable Insight Capital Management LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 1,700 shares of the company’s stock, valued at approximately $276,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $765,000. Duality Advisers LP grew its stake in Johnson & Johnson by 91.6% during the 1st quarter. Duality Advisers LP now owns 43,131 shares of the company’s stock valued at $6,823,000 after acquiring an additional 20,615 shares in the last quarter. Empirical Finance LLC boosted its holdings in shares of Johnson & Johnson by 3.2% during the 1st quarter. Empirical Finance LLC now owns 91,730 shares of the company’s stock worth $14,511,000 after purchasing an additional 2,883 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Johnson & Johnson by 11.4% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 125,694 shares of the company’s stock worth $19,884,000 after buying an additional 12,847 shares in the last quarter. Finally, Stokes Family Office LLC grew its holdings in Johnson & Johnson by 0.3% in the 1st quarter. Stokes Family Office LLC now owns 71,297 shares of the company’s stock valued at $11,278,000 after buying an additional 243 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $155.47 on Monday. The company’s 50 day simple moving average is $162.61 and its 200-day simple moving average is $155.86. The firm has a market cap of $374.31 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.66 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.19%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Cowen decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $175.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.